United States-based Goldfinch Bio announced on Friday that it has signed a license agreement with Japan-based Takeda Pharmaceutical Company Limited for global rights to a preclinical, peripherally-restricted cannabinoid receptor 1 monoclonal antibody.
Goldfinch Bio will assume all development and commercialisation responsibilities for the treatment of rare and metabolic kidney diseases worldwide. The contract grants Takeda the option, prior to the start of pivotal studies, to request that Goldfinch Bio negotiates with Takeda for sub-licensing of Japanese rights to Takeda.
Financial terms of the deal were not revealed. Goldfinch Bio plans to file an investigational new drug application for this CB1 inhibitor, re-named GFB-024, in the second half of 2020.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer